The firm plans to build on its organ and tissue modeling technology to develop more sophisticated tests, including full-body digital twins.
Blincyto plus chemo was approved for adult patients with Ph-negative, CD19-positive, and MRD-negative B-cell precursor acute lymphoblastic leukemia.
In a previous trial, patients with RSK2-high cancers had a significantly greater benefit from treatment with PMD-026 than those with RSK2-low cancers.
Bluebird Bio has commercialized three gene therapy products, including one of the first for sickle cell disease, but would soon run out of cash.
Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.